Ask questions below and receive answers directly from the target company's team members.
Please post your question in English so that all of our investors are able to participate in the discussion.
anonymous 3 days ago
If round is successful, where are the stocks stored after that?(Invesdor Ownersportal, Bookentry system, Shareholder list)
JKL 5 days ago
What is the plan if you are not able to raise minimum (500k EUR) till end of January? Currently I am seeing this quite big risk.
anonymous 7 days ago
In the 2017 you projected the 2019 revenue as high as 4 655 000€ whereas now you state that it's going to be only 7 945€. What went wrong and what did you learn from that?
anonymous 7 days ago
In 2017 Askel Healthcare raised 450 024€ on the Invesdor platform. That time you valued the company at 2 100 000€ with 1 share being 196.26€. Why is the value of 1 share today 3,20€ even though you value the company at 5 008 393€? Share price dropping from almost 200€ to 3,20€ is quite significant, how have the existing share owners reacted to this?
anonymous 16 days ago
Dear Askel Board Members, I am impressed by your business plan and baed on that there is a significant market potential for your products. I am slightly concerned about the cash flow projections. Based on the financial projections your cumulative EBITDA for period 2020-2022 is negative €4.1m. This assumes that your veterinary product sales grow from practically from zero to €600.000 in less than 3 years. Assuming average product sells for €600, you are expecting to sell roughly 1.000 products in 2022. That’s not unrealistic. It feels to me that the plan to raise funds from this funding round (up to €1m), value-add investors (~€2m) and EIC/Business Finland (€4.5m), totalling up to €7.5m, is reasonable but represents a significant cash-flow risk if the funding doesn’t materialise as planned. My concern concern regarding the cash flow projection is threefold: a. if the sales growth for some reason does not materialise as planned your EBITDA will be more negative and it will make it harder to raise the €2m from your value-add investors; b. if I understand correctly, the EIC/Business Finland funding is leveraged agains the €2m from value-add investors’ investment, and if that does not materialise then you can not raise the €4.0-4.5m from EIC/Business Finland; c. if you can’t raise the above funding, based on the EBITDA projection, you will run out of cash before 2022. My questions are: a. how secure is the value-add funding? Have potential investors been identified already? if the sales are not growing to plan how much are you prepared to dilute the shares in order to raise the necessary funds from the value-add investors?; b. would you be able to give some more details on the sales growth of the current product? what is the plan to achieve the projected sales in 2022?; c. when are the patents expected to be in place? — Please feel free to correct me if I have misunderstood something. I am looking forward to hearing from you. Many thanks, Joni Sairanen, TidalStone Ltd. (UK)